Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Aligos Therapeutics (NASDAQ: ALGS), a clinical stage biopharmaceutical company specializing in liver and viral disease therapies, has announced the granting of inducement stock options to new employees. The Compensation Committee approved non-qualified stock options to purchase 26,000 shares, granted on June 10, 2025, under the company's 2024 Inducement Plan. These grants, made in accordance with Nasdaq Listing Rule 5635(c)(4), have an exercise price matching Aligos' closing stock price on the grant date. The options will vest over four years, with 25% vesting after one year and the remainder vesting monthly, contingent on continued employment.

Positive

• Company is actively recruiting and expanding its workforce
• Structured vesting schedule helps retain talent over a 4-year period

Negative

• Potential dilution of existing shareholders through new stock options
• Additional compensation expenses impact on company financials

SOUTH SAN FRANCISCO, Calif., June 13, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, “Company”), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that the Compensation Committee of the Company’s Board of Directors granted non-qualified stock options to purchase an aggregate of 26,000 shares of the Company’s stock (the “Inducement Grant”) to newly hired employees on June 10, 2025 (the “Grant Date”), in connection with the commencement of employment.

The Inducement Grants were granted pursuant to Aligos’ 2024 Inducement Plan (the “Plan”) as an inducement material to these individuals entering employment in accordance with Nasdaq Listing Rule 5635(c)(4). The Plan is used exclusively for the grant of equity awards to individuals who were not previously employed by Aligos.

The Inducement Grants have an exercise price per share equal to the closing price of Aligos’ common stock on the Grant Date. The shares subject to the Inducement Grant will vest over a four-year period, with 25% vesting on the first anniversary of the Grant Date and the remainder vesting in equal monthly installments, subject to the continued employment through the applicable vesting dates.

About Aligos

Aligos Therapeutics, Inc. (NASDAQ: ALGS) is a clinical stage biopharmaceutical company founded with the mission to improve patient outcomes by developing best-in-class therapies for the treatment of liver and viral diseases. Aligos applies its science driven approach and deep R&D expertise to advance its purpose-built pipeline of therapeutics with high unmet medical needs such as chronic hepatitis B virus infection, metabolic dysfunction-associated steatohepatitis (MASH), and coronaviruses.

For more information, please visit www.aligos.com or follow us on LinkedIn or X.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this press release that are not historical facts may be considered “forward-looking statements,” including without limitation, statements regarding Aligos’ mission to improve patient outcomes by developing best-in-class therapies for the treatment of liver and viral diseases. Such forward-looking statements are subject to substantial risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties inherent in the drug development process, including Aligos’ clinical stage of development, the process of designing and conducting clinical trials and the regulatory approval processes. For a further description of the risks and uncertainties that could cause actual results to differ from those anticipated in these forward-looking statements, as well as risks relating to the business of Aligos in general, see Aligos’ Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 6, 2025 and its future periodic reports to be filed or submitted with the Securities and Exchange Commission. Except as required by law, Aligos undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances, or to reflect the occurrence of unanticipated events.

Aligos Therapeutics

Contact
Jordyn Tarazi
Vice President, Investor Relations & Corporate Communications
+1 (650) 910-0427
jtarazi@aligos.com

FAQ

What is the size of the stock option grant announced by Aligos Therapeutics (ALGS)?

Aligos Therapeutics granted non-qualified stock options to purchase 26,000 shares to newly hired employees on June 10, 2025.

What is the vesting schedule for ALGS's inducement grants announced in June 2025?

The stock options vest over 4 years, with 25% vesting on the first anniversary and the remainder vesting in equal monthly installments, subject to continued employment.

Why did Aligos Therapeutics (ALGS) issue these inducement grants?

The inducement grants were issued as material incentives to attract new employees to join the company, in accordance with Nasdaq Listing Rule 5635(c)(4).

What is the exercise price for Aligos Therapeutics' June 2025 inducement grants?

The exercise price equals Aligos' common stock closing price on the grant date of June 10, 2025.

What is Nasdaq Listing Rule 5635(c)(4) that ALGS referenced in their announcement?

This Nasdaq rule allows companies to grant equity as inducement awards to new employees without shareholder approval, provided they are material to the individual's decision to join the company.